Sermorelin Acetate Powder

In the diagnosis and treatment of chronic diseases in pets, nutritional loss and metabolic disorders are key bottlenecks restricting therapeutic effects and pet quality of life, which are particularly common in wasting diseases such as chronic kidney disease, chronic liver disease, diabetes mellitus, and tumors. With its unique chemical properties and physiological mechanism of action, the product exhibits significant advantages in nutritional supplementation and metabolic regulation for pets with chronic diseases. Its amphoteric ionization property enables adaptation to different pH environments in the pet body; the improved bioavailability conferred by acetate modification ensures conditioning efficacy; and its high-purity trait guarantees the safety of long-term use in pets with chronic diseases.

Nutritional Maintenance and Metabolic Regulation for Chronic Kidney Disease (CKD)

Chronic kidney disease is one of the most prevalent chronic conditions in dogs and cats. During the disease course, the decline in glomerular filtration function easily triggers complications such as protein metabolic disorders, muscle loss, anemia, and electrolyte imbalance. Among these, weight loss and muscle atrophy are core factors leading to poor prognosis. As a stimulant of endogenous growth hormone secretion, Sermorelin Acetate Powder provides targeted nutritional support for CKD pets by precisely regulating metabolic pathways.

Hepatocellular Repair and Metabolic Improvement for Chronic Liver Disease

Chronic liver diseases in dogs and cats, such as chronic hepatitis and cirrhosis, are often accompanied by hepatocyte damage and decreased liver function, which in turn lead to insufficient protein synthesis, fat metabolic disorders, jaundice, and other symptoms. The core chemical properties of the product lay the foundation for its application in conditioning pets with liver diseases: its amphoteric ionization property can adapt to pH changes in the hepatic microenvironment, ensuring stable efficacy across different disease stages; its high-purity characteristic prevents secondary irritation of damaged liver tissue by impurities.

Nutritional Support for Cancer Cachexia

Pet tumors, especially malignant ones, induce a state of high metabolism in the body through the abnormal proliferation of tumor cells, resulting in severe anorexia, cachexia, rapid weight loss, and other wasting symptoms in pets, which drastically reduce their quality of life. The product provides nutritional support for tumor-bearing pets through dual pathways: on the one hand, by stimulating endogenous growth hormone secretion, it regulates the appetite center, enhances pets' willingness to eat, and increases calorie and nutrient intake; on the other hand, it promotes protein synthesis and energy metabolism, helps pets maintain physical strength, reduces muscle loss caused by tumor consumption, and gains time for tumor treatment modalities such as chemotherapy and surgery.Its mild mechanism of action does not directly stimulate tumor cells nor interfere with the efficacy of anti-tumor drugs, making it an ideal choice for palliative care and nutritional support in pets with cancer.

Inside the pet's body, the improved liposolubility enables the substance to be rapidly absorbed into the bloodstream, directly targeting the pituitary gland to stimulate the pulsatile secretion of endogenous growth hormone. As a core metabolic regulatory hormone, growth hormone can activate the Insulin-like Growth Factor-1 (IGF-1) pathway, promoting protein synthesis and inhibiting protein breakdown, while accelerating lipolysis for energy supply. This achieves the metabolic regulatory effect of "muscle gain and fat loss", which precisely meets the nutritional needs of pets with chronic diseases.

Amphoteric Ionization Property Adapting to the Complex Metabolic Environment in Vivo

The internal environment of pets with chronic diseases is often accompanied by pH disorders. For instance, pets with Chronic Kidney Disease (CKD) are prone to metabolic acidosis, while those with chronic liver disease may suffer from acid-base imbalance due to cholestasis.

It exhibits typical amphoteric ionization properties with an isoelectric point of approximately 8.2, which allows it to flexibly convert into cationic, anionic or zwitterionic forms in different pH environments. This property ensures its stable existence in the complex acid-base environment inside the pet's body, preventing structural damage or activity loss caused by pH fluctuations, thus guaranteeing the continuity of its metabolic regulatory effect. For example, in the metabolic acidosis environment (pH < 7.35) of CKD pets, the substance mainly exists in the cationic form, but can still efficiently bind to the growth hormone-releasing hormone receptors of the pituitary gland and initiate the metabolic regulation pathway.

Due to the presence of multiple amino and carboxyl functional groups in its peptide chain structure, this substance exhibits typical amphoteric ionization properties. Its isoelectric point (pI) is approximately 8.2, allowing it to flexibly switch its existing form in different pH environments: when the ambient pH is less than 8.2, it mainly exists in the cationic form; when the pH is greater than 8.2, the anionic form dominates; and when the pH equals the isoelectric point, it presents as a zwitterionic state. This property enables it to be compatible with buffer systems of different pH values, laying a chemical foundation for reconstitution administration and formulation development.

Acetate modification is one of its core chemical characteristics, where acetate ions form a weak electrolyte bond with the amino groups of the peptide chain. This binding method offers dual advantages: on the one hand, it does not damage the core bioactive sites of the peptide chain, ensuring that its biological function of stimulating endogenous growth hormone secretion remains unaffected; on the other hand, it significantly enhances the liposolubility of the substance, promotes the absorption of peptide molecules by the body, and thereby improves bioavailability, addressing the pain points of poor liposolubility and low absorption efficiency of unmodified polypeptides.

With the advancement of diagnosis and treatment standards for chronic diseases in pets, personalized nutritional and metabolic conditioning has become a core component in improving pets' quality of life and prolonging their survival periods.

The product, relying on its unique chemical properties and precise metabolic regulatory effects, boasts broad application prospects in the field of chronic disease management for pets. In the future, leveraging the flexibility of its powder dosage form, researchers can further develop more convenient administration formulations, such as sublingual tablets and nasal sprays, to enhance medication compliance in pets. Meanwhile, targeted compound conditioning regimens can be developed based on the pathological characteristics of different chronic diseases, combining ingredients like probiotics and antioxidants to achieve multi-targeted nutritional and metabolic regulation.